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Tissue progenitor cells are an attractive target for regenerative
therapy. In various organs, bone marrow cell (BMC) therapy has
shown promising preliminary results, but to date no definite mech-
anism has been demonstrated to account for the observed benefit
in organ regeneration. Tissue injury and regeneration is invariably
accompanied by macrophage infiltration, but their influence upon
the progenitor cells is incompletely understood, and direct signaling
pathways may be obscured by the multiple roles of macrophages
during organ injury.We therefore examined amodel without injury;
a single i.v. injection of unfractionated BMCs in healthy mice. This
induced ductular reactions (DRs) in healthy mice. We demonstrate
that macrophages within the unfractionated BMCs are responsible
for the production of DRs, engrafting in the recipient liver and local-
izing to the DRs. Engrafted macrophages produce the cytokine
TWEAK (TNF-like weak inducer of apoptosis) in situ. We go on to
show that recombinant TWEAK activates DRs and that BMC medi-
ated DRs are TWEAK dependent. DRs are accompanied by liver
growth, occur in the absence of liver tissue injury and hepatic pro-
genitor cells can be isolated from the livers ofmicewith DRs. Overall
these results reveal a hitherto undescribed mechanism linking mac-
rophage infiltration to DRs in the liver and highlight a rationale for
macrophage derived cell therapy in regenerative medicine.
liver regeneration | adult stem cell
Tissue progenitor cells show promise as a regenerative thera-peutic target in a variety of organs (1, 2). Within the liver,
hepatocytes regenerate the liver efficiently but following severe
injury hepatocyte regeneration may fail and a second regenerative
compartment becomes activated. Ductular reactions (DRs) are
seen in the liver and contain the population of hepatic progenitor
cells (HPCs). DRs have been used to describe the activated biliary
epithelial cells and their associated inflammatory reaction. Here
wewill use the termDR to refer to the epithelial component alone.
HPCs are bipotential adult stem-like cells that are thought to re-
side in the smallest branches of the biliary tree and are defined
through their capacity to differentiate under clonogenic conditions
in vitro into hepatocytes and biliary epithelial cells (3, 4). DRs are
found in almost all major forms of human liver disease, as well as in
a variety of animal models of both chronic and severe acute liver
injury (5). A correlation exists between the extent of liver disease
and magnitude of accompanying DRs (6, 7). The therapeutic
manipulation of DRs and HPCs offers the potential to regenerate
severely injured liver without recourse to liver transplantation (8).
Whereas transplantation of HPCs has been successful in rodents
(9), isolation of human HPCs is not a practical therapeutic option
(10). Manipulation of the liver’s endogenous DRs and HPCs rep-
resents a more realistic therapeutic approach (11, 12).
There is no accepted marker specific for HPCs as the markers
that have been used to isolate HPCs are also expressed upon
bile duct cells, and DRs. Cytokeratins (CK) 7 and 19, EpCAM
(Epithelial Cell Adhesion Molecule), Dlk1 (Delta Like Homolog),
MIC1-1C3, and Sox9 [sex determining region Y (SRY) box] are all
accepted, albeit unspecific, markers of DRs, and have been used to
define essential mediators, including many cytokines, which con-
trol the DR response to experimental liver injury (5, 13–15).
Among the most recently identified of these paracrine signals is
TNF-like weak inducer of apoptosis (TWEAK), a cytokine of the
TNF family, which directly stimulates proliferation of DRs in vivo
and HPCs in vitro (16, 17).
During liver injury, macrophages are recruited from the bone
marrow (BM) to engraft within the liver adjacent to DRs (18).
Regeneration of any organ in response to injury is accompanied
by macrophage infiltration, which is believed primarily to clear
cellular debris. However, following tissue injury macrophages
have other roles in tissue repair, which include a role in influ-
encing stem and progenitor cell behavior (4, 19).
Related work in other organs has reported that even in the ab-
sence of their own prolonged engraftment, BM-derived cells may
stimulate tissue progenitor cells, a process that is speculated to be
reliant on paracrine signaling (20). Nonetheless, interpretation of
a direct paracrine pathway from BM-derived cells to tissue pro-
genitor cells is complicated during tissue injury by the association
of local inflammation and tissue remodeling, processes that are
affected by BM-derived cells (21, 22) and that also indirectly in-
fluence tissue progenitor cell activation (23).
The BM represents a readily available, autologous source of
cells for cell therapy. Recent studies in patients with liver injury
have suggested that i.v. delivery of whole bone marrow cells
(BMCs) may have beneficial effects, potentially improving liver
regeneration and function (2). Earlier reports that BMCs could
themselves adopt an epithelial phenotype in the liver have proven
to be unfounded (24). A recent study by us in a chronic liver injury
model has shown infusion of BM-derived macrophages improves
fibrosis and is associated with improved liver function (22).
However, a direct effect of macrophages upon the DRs or HPCs
themselves has not been shown. The reduction of liver fibrosis
itself is associated with improved hepatic regeneration (25) and
the degree ofmatrix remodeling correlates to themagnitude of the
DR response (23). Furthermore macrophages themselves are
critical for the reduction in fibrosis (21). All these factors mean
that the study of a direct effect of macrophages upon DRs
becomes near impossible in the setting of chronic liver injury.
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Therefore, we investigated the existence of a paracrine stimu-
lation directly by BMCs upon ductular cells in normal murine
liver. Here we report that BMC transfer activates the pro-
liferation of DRs in the absence of liver injury. This has enabled
the analysis of the direct effect of macrophages upon DRs in the
absence of confounding matrix changes, inflammation, and tissue
damage. This DR activation is due to paracrine, macrophage-
derived, TWEAK signaling. The understanding of both the sig-
naling mechanisms mediating DR activation, and the cell type
responsible for this, may enable the development of novel ther-
apies to stimulate liver regeneration.
Results
Transfer of Syngeneic BMCs to Healthy Mice Results in Ductular
Activation in Healthy Recipient Mice. To allow tracking of donor-
derived BMCs in uninjured recipient liver tissue, initial observa-
tions were made in female mice that received a single transfer
of 107 unfractionated BMCs from male donors. These animals
showed a consistent, periportal expansion of panCK+, Dlk1+,
EpCAM+, and Sox9+DRs, from day 7 post transfer, which lasted
for up to 6 wk (Fig. 1A and Fig. S1A). No evidence of hepato-
cellular injury or inflammation was observed in recipient livers at
any time point (Fig. 1A and Fig. S1A). Irradiation of BMCs before
injection rendered them incapable of inducing ductular activation
(Fig. 1 A and B and Fig. S1A), implying a requirement for func-
tionally intact BMCs and arguing against the involvement of ei-
ther a bystander reaction to debris or immunogenic antigens via
a minor histocompatability reaction. Syngeneic (inbred female to
female) cell transfer yielded an identical ductular activation to
that observed in sex-mismatched transfer experiments (Fig. 1C).
Again, ductular expansion began as early as 1 d following transfer
and progressed over 3–6 wk (Fig. 1 D and E).
Although liver weight fell initially following BMC transfer,
relative liver size increased in association with ductular expansion,
resulting in consistently larger livers 6 wk following BMC therapy
versus PBS control (Fig. 1F). Whole liver albumin gene expression
increased following BMC transfer, although later this gradually
normalized (Fig. S1B). No long-term changes were seen in livers
of mice followed for 400 d following BMC transfer (Fig. S1C).
Identical ductular expansion was observed when BMCs from aged
donors was delivered to healthy young mice (Fig. S1 D and E).
BM Transfer Results in Transient Liver Engraftment by Donor-Derived
Macrophages. Two independent cell-tracking strategies were used
to study BMC fate in recipient livers: Y chromosome detection
in a sex-mismatched BMC therapy and GFP mismatch, whereby
GFP+ donor BMCs were delivered to WT littermates. Both anal-
yses found transient engraftment in the liver by donor-derived cells,
with no evidence of transdifferentiation of donor BMCs into
panCK+ DRs or hepatocytes (Fig. 2). Six hours and 1 d following
transfer, donor cells were seen throughout all zones of the he-
patic lobule with no specific localization (Fig. 2 A and B, re-
spectively). From day 3, however, donor-derived cells were found
directly adjacent to DRs and make physical contact with the
panCK+ DRs (Fig. 2C), at which time F4/80+ macrophages also
make contact with panCK+ DRs (Fig. 2D). To characterize the
phenotype of engrafted donor-derived cells, FACS selection of
GFP+ cells in WT liver was performed 3 d after BMC delivery
from GFP+ donors. The resultant cell isolate was exclusively
CD45+ (Fig. S2C) and by majority F4/80+ macrophages (81%);
this was confirmed by combining in situ hybridization for the Y
chromosome and F4/80 immunostaining (Fig. 2E). Donor cells
were consistently undetectable in recipient livers by 42 d post-
injection (Fig. 2F). Therefore, the expansion of panCK+ DRs
occurred principally following the loss of engrafted donor-
derived cells.
Fig. 1. Ductular reactions occur following bone marrow cell (BMC) transfer.
(A) Absence of injury with simultaneous expansion of panCK+/Sox9+ DRs in
female mouse liver 42 d following tail vein injection of 107 BMCs, additional
ductular markers (EpCAM and Dlk1 shown in Fig. S1A). Male BMC transfer
experiments were repeated four times, each with n = 5 animals per group.
(B) Quantification of DRs 42 d after transfer of 107 male BMCs. (C) Sox9+ (21
d) and (D) PanCK+ DRs in inbred female recipients of syngenic BMC transfer
with corresponding DR quantification over time (E). Proliferation of DRs is
seen as early as 1 d following cell transfer (Inset BrdU 2 h before tissue
harvest), with progressive expansion over subsequent 3 wk. Data are pre-
sented as relative change in cells per 200× magnification field (experimental
mean/time matched control mean) ± SEM. Mean panCK+ ductular cells 34.0
± 2.4, 36.1 ± 4.9, 41.9 ± 2.1, and 35.6 ± 4.2 for days 3, 7, 21, and 42, re-
spectively following BMC transfer. (F) Initial reduction in liver size is fol-
lowed by increase in relative liver weight (liver weight/body weight)/(control
liver weight/body weight) over the period of ductular expansion (n ≥ 4 each
group). Data are presented as mean number of cells per field ± SEM. P values
denote Student t test result vs. control.
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Macrophages Are Themselves Capable of Activating a Ductular Reaction.
The experiments described above suggest a central role for mac-
rophages in the activation of DRs following BMC injection. We
therefore hypothesized that in vitro matured macrophages would
stimulate a similar DR response to whole BMCs. Macrophage cell
transfer resulted in activation of DR proliferation, analogous to
that seen with BMCs (Fig. 3 A–D and Fig. S3D), once again in the
absence of hepatocellular injury (Fig. S3 E and F). A raised serum
alkaline phosphatase together with expression of other biliary/DR
marker genes was also observed in mice receiving macrophage
transfer (Fig. S3 G–L). Increased serum albumin was observed
21 d following macrophage cell transfer (Fig. 3E).
To examine the role of the macrophage subpopulation within
whole BM, whole BMCs were isolated from donor CD11b-diph-
theria toxin (DT) receptor (DTR) mice and transferred to healthy
WT littermates. DT was then used to selectively deplete donor-
derived CD11b+ macrophages from the transferred population;
then the resultant DR response in recipients was measured (Fig.
3F). Sole depletion of donor CD11b+ macrophages from whole
BMCs resulted in reduction of recipient panCK+ DR expansion
(Fig. 3G). At 21 d, a time when donor cells were undetectable, host
liver macrophage numbers significantly increased (Fig. S3M).
Functional Effects of DR Activation Following Macrophage Transfer.
While demonstrating expansion of cells expressing DR markers
in vivo, we wished to functionally observe the effect of these ex-
panded DRs containing putative HPCs following macrophage/
BMC transfer. At the time of previously observed liver enlargement
following BMC transfer, Sox9 staining revealedmultiple larger cells
with hepatocyte-like morphology and Sox9+ nuclei (Fig. 4A) adja-
cent to smaller Sox9+DRcells, implying differentiation ofDRs into
functional parenchyma. In agreement with the proliferation and
differentiation of DRs into hepatocytes, BrdU label was taken up
by DRs 21 d following macrophage transfer (Fig. 4B). A further 4 d
later evidence of both retention of BrdU label within clusters of
DRs was observed (Fig. 4C) together with BrdU label in both
ductular cells and hepatocytes adjacent to one another (Fig. 4 D
and E). A functional assessment for the presence of HPCs was
performed 3 wk following macrophage cell transfer (Fig. 4F). Using
FACS, Ter119−/CD31−/CD45−/CD24+/EpCAM+ cells were iso-
lated (Fig. 4F). This population was significantly increased (ap-
proximately threefold) in healthy livers following macrophage cell
transfer vs. PBS control (total pooled Ter119−/CD31−/CD45−/
CD24+/EpCAM+ cells from three livers = 3,600 vs. 1,200 cells,
respectively; Fig. 4G). Following macrophage injection, we found
an increase in cells with HPC-defining characteristics i.e., colony
formation from clonal density growth in vitro with the resultant
cells of both a hepatocellular and biliary morphology (Fig. 4H) that
could be maintained in the long term and passaged. A total of six
viable clonal colonies were obtained after 2 mo from 3,600 sorted
Ter119−/CD31−/CD45−/CD24+/EpCAM+ cells in the macrophage
Fig. 2. Transfer of BMCs leads to transient hepatic engraftment of macro-
phages. (A) Engraftment of GFP+ cells within the liver 6 h following tail vein
injection of 107 GFP+ cells into WT mice. Portal tract highlighted by arrow.
(B) One day following sex-mismatched BMC transfer, donor-derived cells
remain scattered through hepatic parenchyma. Confocal analysis of recipi-
ents using panCK immunohistochemistry (red) and Y chromosome FISH
(green, white arrows) with DAPI (blue). (C) Confocal analysis 3 d following
sex-mismatched BMC transfer reveal association of donor-derived cells with
panCK+ ductular cells. No evidence of transdifferentiation of donor cells to
hepatocytes or ductular cells (A–C). Male and female controls (Fig. S2 A and
B). (D) Dual immunohistochemistry for F4/80 (red) and panCK (green) con-
firms their association 3 d following BMC transfer. (E) Donor-derived cells (Y
chromosome, green) express macrophage markers (F4/80, red) on micro-
scopic analysis 3 d following sex-mismatched BMC transfer. Inset: represen-
tative F4/80 immunocytochemistry performed on GFP+ cells sorted by FACS
from the nonparenchymal fraction of digested liver 3 d following GFP-mis-
matched BMC transfer. (F) Quantification of engrafted donor cells from
whole liver by real-time PCR of genomic DNA in sex-mismatched BMC
transfer model and in the nonparenchymal cell (NPC) fraction by FACS for
GFP in GFP-mismatched BMC transfer (Fig. S2C). PCR data (blue) is presented
as group mean n = 2 at each time point. FACS data (green) are presented as
fraction of the NPC population; each data point represents pooled cell
populations, n = 5.
Fig. 3. Macrophage transfer recapitulates whole BMC transfer. Twenty-one
days following infusion of 107 syngenic macrophages expansion of panCK+
DRs is observed, reproducing both morphologically (A) and quantitatively (B)
the expansion seen with BMC (each group n = 5). Expansion of A6+ and
MIC1-1C3+ DRs is also observed (C and Inset, respectively), together with
active proliferation of Ki67+/panCK+ ductular cells (D). (E) Raised serum al-
bumin is observed 21 d following macrophage transfer. (F) Macrophage
depletion was performed by delivering 107 BMCs from CD11b-DTR mice to
WT littermates. DT was given on 0, 3, and 6 d post-BMC transfer to deplete
donor-derived macrophages. Tissue was analyzed at 21 d (n ≥ 5 each group).
Control mice received PBS injection instead of DT. (G) Following transfer of
107 BMCs from CD11b-DTR donors. Data are presented mean ± SEM, P values
denote two (E) and one (B and G) tailed Student t test.
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recipient group (from n = 3 whole livers); in the PBS recipient
group there were no viable colonies formed from the total pooled-
sorted Ter119−/CD31−/CD45−/CD24+/EpCAM+ cells (from n = 3
whole livers). Colonies from the macrophage injected group
expressed the biliary markers Sox9 and MIC1-1C3 together with
the hepatocyte marker HNF4α (Fig. 4 I and J); within colonies,
nuclear Hepatocyte Nuclear Factor 4α (HNF4α) expression was
heterogenous with some cells exhibiting reduced nuclear HNF4α
expression (Fig. 4K).
DR Activation Following BMC Transfer Is Dependent on TWEAK
Signaling. To determine the mechanism by which engrafted BM-
derived macrophages stimulate the DR, we screened whole liver
RNA for the presence of growth factors known to be associated
with ductular proliferation, including: Hepatocyte Growth Factor
(HGF), IFNγ, TNF, IL6, Lymphotoxin α (LTα), LTβ, Oncostatin
(OSM), and TWEAK. Whereas most of these growth factors
either were undetectable or did not change over the time course
of ductular expansion (Fig. S5 A–D), TWEAKmRNA levels were
strongly induced during the first week following BMC transfer
and returned to normal as engrafted cells were lost from the liver
(Fig. 5A). In vitro maturation of BMCs to macrophages resulted
in a 20-fold up-regulation of TWEAKmRNA (Fig. S5E). To assess
if donor-derived cells were the source of TWEAK message post-
BMC injection, GFP+ donor-derived cells were sorted from
WT recipient livers and examined for TWEAK expression. Rel-
ative to whole BM, TWEAK mRNA levels were 2.8-fold elevated
in the GFP+ pullout fraction (Fig. 5B). Recombinant (r)TWEAK
administered to healthy mice results in expansion of DRs (Fig. 5 C
and D and Fig. S5) and the Fibroblast growth factor-inducible
immediate-early response protein 14 (Fn14) receptor is also
shown to be expressed in both bile ducts and DRs (Fig. 5E), but
not in periportal myofibroblasts (Fig. S5K).
To directly test whether TWEAK signaling mediates DR ex-
pansion following BMC transfer, we used two methods: (i) transfer
of WT BMC into recipient mice lacking the TWEAK receptor
Fn14 (Fn14−/−), and (ii) transfer of BMC lacking TWEAK
(TWEAK−/− donors) into WT recipients and compared the extent
of DR response to appropriate WT controls. In the absence of
recipient Fn14 expression, DRs were reduced (Fig. 5 E and F and
Fig. S5). The engraftment ofWTBMCs into Fn14−/− recipients was
unchanged (Fig. S5H). Whereas a trend was observed for reduced
panCK+DRs in baseline Fn14−/−mice compared with baselineWT
animals (P = 0.098), greater DR expansion (in both absolute and
relative terms) is observed inWT recipients compared with Fn14−/−
recipient mice following infusion of WT BMCs. To eliminate the
differences between Fn14−/− and WT recipient mice in analysis of
ductular expansion, transfer of BMCs from TWEAK−/− donors vs.
WT donors to WT recipients was examined and revealed reduced
DR expansion in the recipients of TWEAK−/−BMCs (Fig. 5G and
H). Both transgenic models of impaired TWEAK/Fn14 signaling
demonstrate the necessity of this signaling pathway for the DR
expansion observed in response to BMC administration.
Discussion
There is an increasing appreciation that BM-derived cells may
influence the regenerative response of an injured organ. Although
paracrine signaling from the BMCs to the target organ has been
suggested to underlie this phenomenon, such signaling has not
been well characterized. Furthermore in the damaged liver any
improvement in regeneration seen following BM injection may be
an indirect phenomena secondary to the effects upon the sur-
rounding matrix (23). Here we have demonstrated that a single
infusion of unfractionated BMCs results in direct activation of
a DR response in the undamaged liver. We show that the mac-
rophage population within unfractionated BMCs is both neces-
sary and sufficient to recapitulate this DR activation. Infusion of
BMCs/macrophages results in changes to both liver structure and
function and includes the expansion of clonogenic HPCs. We go
on to show that TWEAK/Fn14 signaling is a key component of
the macrophage-stimulated DR activation in this context.
Following peripheral venous infusion of BMCs, the donor
derived macrophages transiently engraft within the uninjured
liver in juxtaposition to DRs, analogous to their recruitment
Fig. 4. Functional parenchymal regeneration following BMC transfer. (A)
Twenty-one days following BMC transfer, periportal Sox9+ ductular expan-
sion is observed compared with PBS control, with frequent nuclear Sox9
expression in hepatocyte-like cells adjacent to ductular cells (arrows). Twenty-
one days following transfer of 107 syngenic macrophages mice were ad-
ministered i.p. BrdU and killed either 2 h (B) or 4 d later (C–E), n = 3 each
group. (B) Labeling of panCK+ ductular cells with BrdU 2 h following pulse.
Four days later, evidence of division of BrdU+/panCK+ into two daughter
BrdU+/panCK+ cells (C) and separately into hepatocyte-like cells (D) express-
ing cytochrome P450 (CYP) 2D6 (E). Individual channels and controls are
shown in Fig. S4 A–C. (F) Diagram explaining isolation of FACS sorted viable
(7AAD−), lineage negative (Ter119−/CD31−/CD45−), CD24+/EpCAM+ cells fol-
lowed by their clonal analysis, performed 3 wk following injection with 107
sygenic macrophages or PBS control. (G) Representative CD24+/EpCAM+ plots,
gating strategy is shown in Fig. S4. (H) CD24+/EpCAM+ cells were more frequent
in the lineage negative population by FACS in animals receiving macrophages
than PBS injections (here shown as ameanof n≥ 3 each group); P value denotes
one-tailed Mann–Whitney test. (I) Following up to 56 d plating at clonal density
discrete heterogeneous colonies were identified from the CD24+/EpCAM+ cells
in mice that had received macrophage injection. (J) Colonies expressed Sox9
(Inset Sox9 channel only) and (K) the activated biliary marker MIC1-1C3, to-
gether with hepatocellular differentiation marker HNF4α. (L) Cells at the pe-
riphery of the main colony were negative for nuclear HNF4α.
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during injury (18). Ductular proliferation and liver growth then
occurs, principally following the loss of engrafted cells but with
the additional accumulation of endogenous macrophages, again
mirroring observations in an injury model (22). During the DR,
liver weight transiently increases but without evidence of cellular
enlargement or tissue oedema to account for this change. These
changes are transient with restoration of normal liver architec-
ture and weight in the following 6 wk.
There is an urgent need to develop novel therapies for chronic
liver disease and manipulating the endogenous DR and HPC
populations is a potential option. Previous proof of principle of
pharmacological targeting of the DR has been shown in mice in the
context of liver injury where DRs were inhibited (12). The precise
characterization of hepatic stem cells and HPCs remains conten-
tious with numerous, often nonspecific markers used to identify this
population, although the majority consensus is that HPCs exist
within the biliary tree and DRs. Various cells of the DR have been
demonstrated to be capable of hepatocellular regeneration (9, 14,
15, 26). Following macrophage transfer we go on to show that ac-
companying the DR response identified histologically, there is an
expansion of a defined Ter119−/CD31−/CD45−/CD24+/EpCAM+
cell population in the healthy livers that contains HPCs. This ex-
panded Ter119−/CD31−/CD45−/CD24+/EpCAM+ cell population
forms heterogenous colonies when grown at clonal density ex vivo,
may be passaged, and throughout expresses the same markers as
the expanded cells observed in vivo. The clonal colonies when
formed contain both hepatocellular and biliary markers, indicating
that the isolated and purified HPCs are bipotential and self-
renewing. These markers include MIC1-1C3, identified by Dorrell
et al. following generation of antibodies to murine DRs (27) and
more recently has been shown to select an enriched population of
clonogenic HPCs (15). Our findings therefore highlight a thera-
peutic means by which these host DRs can be directly stimulated
and we propose this pathway as a possible mechanism by which
autologous BMC therapy may be beneficial in human liver disease.
Animal models of BMC therapy for liver disease and clinical au-
tologous BMC therapy studies are underway with encouraging
preliminary results (2, 28–30). A recent report by our group has
shown that a single portal vein injection of macrophages signifi-
cantly reduces fibrosis in a model of chronic liver injury. Alongside
this reduction in fibrosis an improvement in liver function was seen,
including an increase in DRs. The complexity of assigning a cause
and effect relationship is highlighted by the fact that in the chronic
injury model, the macrophages increase recruitment of inflam-
matory cells to the hepatic scar. Subsequent to this, a large number
of matrix metalloproteinases, cytokines, and growth factors were
up-regulated and matrix remodeling took place (22). The model
described here is not confounded by other factors occurring during
injury such as matrix remodeling, inflammation, and necrotic tis-
sue, such that a cause–effect relationship between the injected
cells and the DRs can be established. This has enabled a precise
role for TWEAK to be established using the TWEAK−/− donor
mice and the Fn14−/− recipient mice.
A previous report describes a transgenic mouse, which consti-
tutively overexpresses TWEAK and in which DRs are expanded
Fig. 5. BMC-induced ductular expansion is dependent on in-situ TWEAK
from engrafted macrophages. (A) Whole liver TWEAK mRNA following
syngenic BMC transfer. Values are normalized against PBS control and
expressed as mean ± SEM, n = 5 for each time point. No change was ob-
served in control TWEAK expression over time. (B) TWEAK gene expression
by GFP+ liver engrafted donor-derived cells retrieved by FACS sorting 3 d
following GFP-mismatched BMC transfer. Values are normalized against
whole BMCs control. (C and D) Administration of 0.4 μg i.v. rTWEAK daily for
7 d resulted in expansion of panCK ductular cells in vivo; n = 5 each group,
P value denotes one-tailed Mann–Whitney test (see also Fig. S5). (E and F)
Reduced BMC-mediated ductular expansion from baseline in Fn14−/− mice;
n = 5 each group. BMC to Fn14−/−, 18.8 ± 1.9–27.2 ± 1.4; BMC to WT, 27.1 ±
4.0–42.7 ± 2.3; and PBS to WT, 27.1 ± 4.0−30.6 ± 2.4, baseline to day 21,
respectively (mean ± SEM). Baseline Fn14−/− to WT, P = 0.098. Similar re-
duction in expansion of Sox9+ ductular cells is observed. Fn14 is expressed by
panCK+ ductular cells in WT animals (Inset); individual channels for Fn14/
PanCK are shown in Fig. S5J. A total of 107 BMCs from TWEAK−/− donors
were administered to healthy WT recipients and compared with WT BMC
control for panCK+ ductular expansion at 21 and 42 d (G and H); each group
n = 6. All data are presented as mean ± SEM, with P values denoting two-
tailed Student t test unless otherwise stated.
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(16). We now show that exogenous TWEAK administration re-
sults in DR expansion in vivo and in addition confirm TWEAK
expression by hepatic macrophages and Fn14 expression by
panCK+ DRs, which have been shown to mediate ductular pro-
liferation via NFκB activation (16, 17). Herein we demonstrate a
direct link between macrophage TWEAK production and para-
crine signaling to recipient DRs, resulting in their expansion using
complimentary TWEAK/Fn14 KO models. Similar inhibition of
ductular expansion in both KO scenarios is in keeping with the
monogamous relation between this signal–receptor pair (31).
Ductular expansion has previously been shown to be possible in
the absence of Fn14 expression (17). Regarding the localization
of macrophages to the biliary cells, previous data has described
the recruitment of C-X-C chemokine receptor 4 (CXCR4+) cells
to the biliary tracts via the chemokine Stromal Cell Derived
Factor (SDF)-1 (32, 33). Macrophages strongly express CXCR4,
and this may be a mechanism responsible for cell trafficking in
this model. Interestingly the injected macrophages recruited en-
dogenous macrophages to the liver, which may act to amplify any
macrophage-derived signal.
Following tissue injury, macrophages can modulate progenitor
cell behavior, suggesting a role for these cells in linking injury to
regeneration (4, 19, 20, 34). Our observations both support and
extend this, crucially showing that macrophages are able to mod-
ulate DRs even in the absence of injury. We also describe
TWEAK as a central molecular target for future trophic/small
molecule therapy. Moreover a therapeutic approach to tissue re-
generation based on macrophage therapy offers several advan-
tages: the ready availability of donor cells from an autologous
source; the feasibility of the approach; and a definedmechanism of
action involving paracrine signaling between donor and host liver
cells, without the disadvantages associated with exogenously ad-
ministered stem cells or their derivatives.
Materials and Methods
Animals were housed in a specific pathogen free environment and kept under
standard conditions with a 12 hour day/night cycle and access to food and
water ad libitum. All animal experiments had local ethical approval and were
conducted under UK HomeOffice Legislation. Recipients received 1 ×107 BMCs
via tail vein injection. For details of the animal models used, macrophage
differentiation protocol, harvest of transferred cells, immunohistochemistry,
fluorescence in situ hybridization, real time PCR, statistical analysis, microscopy
and cell counting methodology please see SI Materials and Methods.
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